Nurix Therapeutics, Inc.
NASDAQNurix Therapeutics heads into today's earnings print as one of the more heavily shorted names in clinical-stage biotech, with short sellers retaining a firm grip on the stock. Short interest is running at roughly 21.9% of free float — a level that climbed sharply from around 18.7% in early April and has held near that elevated plateau ever since. The rise of roughly 17% over the…
Snapshot as of 15 May 2026
Nurix Therapeutics heads into today's earnings print as one of the more heavily shorted names in clinical-stage biotech, with short sellers retaining a firm grip on the stock. Short interest is running at roughly 21.9%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NRIX — free to start on ORTEX.
Sign up for free →Open NRIX on ORTEX